Promising results of a clinical trial assessing AbbVie's Venclyxto leukemia drug were shared at the European Hematology Association's recent 22nd annual congress in Madrid.
AbbVie said in a release that Venclyxto (venetoclax), an oral drug that treats chronic lymphocytic leukemia, brought 71 percent of the study’s 158 subjects to either complete or partial remission while meeting other goals established by researchers. The findings assert the level of leukemia cells in patients treated with Venclyxto dropped to barely detectable levels, the release said.
The European Union has green-lighted Venclyxto, a joint creation of AbbVie and Swiss-based Roche, for use against chronic lymphocytic leukemia with specific genetic mutations disrupted by the drug. The drug has also proved effective in cases where patients have relapsed after successful earlier remedies.
A separate Phase 1 study is ongoing to determine Venclyxto’s safety and dose tolerance when used with rituximab. Once these parameters are established, a Phase 2 trial will be underway to determine efficacy against chronic lymphocytic leukemia or small lymphocytic form of the disease.